Latest news with #AragenLifeSciences
New Indian Express
4 days ago
- Business
- New Indian Express
Quadria's oversubscribed fund: What it signals for Asia's healthcare industry
'It reflects the strong global investor confidence in the transformational opportunity within Asian healthcare, where social impact and financial performance go hand in hand,' confirms Abrar Mir, co-founder and managing partner at Quadria Capital. Quadria Capital said in a statement on Tuesday that Fund III drew support from prominent sovereign wealth funds, asset managers, and strategic corporates across North America and Europe. It also secured new commitments from globally recognised institutional investors, with notable participation from leading institutions in the GCC—including Saudi Arabia, the UAE, and Bahrain. In India, the Fund attracted new capital from major banks, insurance companies, and family offices. Additionally, robust re-up commitments from impact investors reaffirm Quadria's dedication to building scalable, high-impact healthcare businesses that deliver lifesaving care to underserved populations across Asia. Asian Healthcare Scenario Currently Asia's healthcare market is estimated to be $5 trillion, and the healthcare industry is reportedly at a pivotal inflection point and will remain a focal area into 2025. "In India, particularly, we're seeing significant investment interest in single-specialty hospitals, diagnostics, medical devices, and pharmaceutical manufacturing—including active pharma ingredients (APIs) and contract (drug) development and manufacturing (CDM). These segments are poised for growth due to increasing healthcare consumption, cost-efficiency initiatives, and deeper technology integration," says Dr Amit Verma, co-founder and managing partner, Quadria Capital. Healthcare growth funds like Quadria's typically provide the industry with strategic guidance and operational support to help scale their businesses and achieve market leadership. Quadria claims that nearly 40% of Fund III is already deployed. Its current investments include Aragen Life Sciences (a global CRDMO serving 400+ pharmaceutical clients), NephroPlus (Asia's largest dialysis chain), and Maxivision (India's leading eye care chain). Two new investments in Southeast Asia are expected shortly, it says. India Impact India is rapidly emerging as a strategic hub for global pharmaceutical and MedTech manufacturing as supply chains diversify, especially with the China plus strategy. While the per capita healthcare spending in India remains low at just $74—far below regional peers like Thailand (US$364) and Malaysia (US$487)—with nearly 50% of healthcare costs still paid out-of-pocket, the healthcare focused funds can catalyse Indian healthcare innovation by strategically investing in high-growth areas such as specialised care and pharmaceutical manufacturing, aiming to create scalable, affordable healthcare solutions for over a billion people.
&w=3840&q=100)
Business Standard
5 days ago
- Business
- Business Standard
Quadria closes $1.07 bn healthcare fund, seeks growth in India and S Asia
Quadria Capital has closed its Fund III at $1.07 billion after exceeding the target to raise $800 million, said the healthcare-focused private equity (PE) firm on Tuesday. The amount raised includes $954 million in primary commitments and $114 million as co-investment capital. A further $300 million is expected to be raised in co-investments later and the total capital available could reach up to $1.3 billion, said the Singapore-based firm in a statement. The amount raised is almost 60 per cent more from the $600 million the company's second plan got in 2020, making III the largest dedicated healthcare PE fund for South and Southeast Asia. 'Asia's healthcare sector is at a pivotal moment, and it will remain in the limelight in 2025, especially with investment interest in India in areas like single speciality hospitals, diagnostic chains, medical devices, and pharmaceutical manufacturing,' said Amit Varma, cofounder and managing partner at Quadria Capital. The sector will grow because of higher healthcare consumption, 'cost-efficiency initiatives and technology integration', he said. Fund III drew participation from existing investors, who boosted their commitments by an average of 80 per cent, as well as global institutions across North America, Europe, the Middle East, and Asia. New backers included sovereign wealth funds, insurance firms, and family offices, particularly from west Asia and India. Fund III is already nearly 40 per cent deployed, with investments in Aragen Life Sciences, NephroPlus, and Maxivision. Two additional transactions in Southeast Asia are expected to close soon, the company said. Founded in 2012, Quadria manages more than $4 billion in assets across 27 companies. The firm said it plans to build a portfolio of about 10 market-leading healthcare businesses with Fund III, through majority and minority stakes, and co-investments.
